Welcome to our book review site go-pdf.online!
You may have to Search all our reviewed books and magazines, click the sign up button below to create a free account.
Antirheumatic Therapy: Actions and Outcomes
Our goal for this book is to examine the contemporary therapy of rheumatoid arthritis (RA) from the increasingly important perspective of impact upon quality of life, costs and long-term health outcomes. For too long the focus has been on short term, symptomatic, and surrogate indicator outcomes. Yet RA is a life-long disor der with the majority of impact on an individual patient many years following onset. Further, even in the short-term, researchers and rheumatologists have tended to emphasize measurements of disease activity such as joint counts, ESR and physi cian's opinion as to the amount of disease activity present. It is only relatively recently that measures of structural damage, qu...
Disease-Modifying Antirheumatic Drugs (DMARDs) in Children with Juvenile Idiopathic Arthritis (JIA)
Juvenile idiopathic arthritis (JIA) is the most common rheumatologic disease in childhood. JIA is an important cause of chronic disease in childhood, with prevalence similar to type I diabetes mellitus. Several classification systems have been used over time to categorize the various categories of juvenile arthritis, including juvenile rheumatoid arthritis (JRA) and juvenile chronic arthritis (JCA), based upon clinical presentation and disease course. In 1995, the International League of Associations for Rheumatology (ILAR) proposed a new classification system, JIA, which consists of seven main categories. These categories are useful in examining potential differences in treatment response a...
Biologic Response Modifier Agents as First-line Treatment for Patients with Rheumatoid Arthritis
Rheumatoid arthritis (RA) is a chronic inflammatory disease that affects approximately 300,000 Canadians. It is characterized by pain, swelling and progressive joint damage, an increase in morbidity and mortality, and a reduction in quality of life and daily activities. Traditional disease modifying antirheumatic drugs (DMARDs) such as methotrexate (MTX), leflunomide, sulfasalazine and hydroxychloroquine, have been shown to modify the clinical course of RA and to slow or stop radiographic progression. The newer biologic disease modifying agents target specific mechanisms of inflammation and have increased the therapeutic options for patients with RA. In Canada, these agents include the tumor...
New Developments in Antirheumatic Therapy
At present we may be at the cross-roads in the therapeutic approaches we have for the treatment of the 100 or more rheumatic conditions. This is be cause we now recognise that although some advances have been made with the development of a large range of non-steroidal and steroidal drugs during the past two decades or so, we now recognise that many, if not all, of these have rather limited effects on many of the disease processes which underlie the manifestations of the various rheumatic states. Advances in molecular bi- 010gy in the past 5-10 years have enabled these tools to be applied extensive ly for developing further our understanding of the rheumatic disease processes. In some cases t...
Biologic response modifier agents as first-line treatment for patients with rheumatoid arthritis
Rheumatoid arthritis (RA) is a chronic inflammatory disease that affects approximately 300,000 Canadians. It is characterized by pain, swelling and progressive joint damage, an increase in morbidity and mortality, and a reduction in quality of life and daily activities. Traditional disease modifying antirheumatic drugs (DMARDs) such as methotrexate (MTX), leflunomide, sulfasalazine and hydroxychloroquine, have been shown to modify the clinical course of RA and to slow or stop radiographic progression. The newer biologic disease modifying agents target specific mechanisms of inflammation and have increased the therapeutic options for patients with RA. In Canada, these agents include the tumor...
Anti-Inflammatory and Anti-Rheumatic Drugs
First published in 1985: This book is an attempt to bring together the diverse information on the basic processes underlying the clinically-observed and experimentally induced inflammatory processes, the actions of traditional and new non-steroidal anti-inflammatory and anti-rheumatic drugs.
Disease-modifying Antirheumatic Drugs (DMARDs) in Children with Juvenile Idiopathic Arthritis (JIA)
OBJECTIVES: To summarize the benefits and harms of disease-modifying antirheumatic drugs (DMARDs) compared to conventional treatment (non-steroidal anti-inflammatory drugs [NSAIDs] and/or intra-articular corticosteroids) with or without methotrexate, and of the various DMARDs compared to one another, in children with juvenile idiopathic arthritis (JIA); and to describe selected tools commonly used to measure clinical outcomes associated with JIA. DATA SOURCES: MEDLINE, EMBASE, and the Cochrane Database of Systematic Reviews. Additional studies were identified from the review of reference lists. REVIEW METHODS: To evaluate efficacy, we included prospective trials that included a comparator an...
Biologics for the Treatment of Rheumatoid Arthritis
This book provides a comprehensive overview of the available biologic therapies whilst comparing them to standard disease modifying anti-rheumatic drugs, and discusses how best to determine which therapy is most appropriate for an individual patient in the framework of current guidelines. Biologics for the Treatment of Rheumatoid Arthritis is an up-to-date and concise practical guide to the latest therapeutic developments in this field. This book is an invaluable source of topical information for all rheumatologists and health care professionals treating patients with rheumatoid arthritis.
Rheumatoid arthritis
The aim is to induce early clinical remission with prompt diagnosis and timely introduction of disease-modifying antirheumatic drugs (DMARDs). Diagnosis is primarily based on history and examination of the joints. Inflammatory laboratory markers (CRP and ESR) may be normal. The presence of anti-cyclic citrullinated peptide (anti-CCP) antibodies is more specific for rheumatoid arthritis (RA) than the presence of rheumatoid factor. If RA is strongly suspected (polyarthritis) the patient must be referred to specialist care without delay. The combination of several drugs is more effective than monotherapy. Over half of patients with early RA are rendered asymptomatic with combination therapy (methotrexate + sulfasalazine + hydroxychloroquine + low-dose prednisolone) . If sufficient response is not achieved with the above-mentioned therapy, treatment with biological agents (biological response modifiers, biologics) is started. Glucocorticoids should not be started in primary care since they may delay diagnosis and hamper the assessment of disease severity.
